PAMS
CBAY

Pictet Asset Management (Switzerland)’s Cymabay Therapeutics CBAY Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$117K Sell
10,641
-5,066
-32% -$47.2K ﹤0.01% 1830
2023
Q1 		$137K Buy
+15,707
New +$126K ﹤0.01% 1811

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s CBAY Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) reduced its Cymabay Therapeutics (CBAY) stake by 32% in Q2 2023, selling an estimated $47.2K and leaving 10,641 shares worth $117K. The position accounts for ﹤0.01% of the portfolio, ranked #1830.

Pictet Asset Management (Switzerland) first reported a position in CBAY in Q1 2023 and has held it in 2 quarters since. The position peaked at $137K in Q1 2023. 151 funds tracked by Wall St. Rank hold CBAY as of Q2 2023.

  • Pictet Asset Management (Switzerland) held 10,641 shares of Cymabay Therapeutics worth $117K as of Q2 2023.
  • Pictet Asset Management (Switzerland) sold 5,066 Cymabay Therapeutics shares in Q2 2023, an estimated $47.2K.
  • Cymabay Therapeutics made up ﹤0.01% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #1830 holding.
  • Pictet Asset Management (Switzerland) first reported a position in Cymabay Therapeutics in Q1 2023 and has held it in 2 quarters since.
  • Pictet Asset Management (Switzerland)'s Cymabay Therapeutics position peaked at $137K in Q1 2023.
  • 151 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.